A Phase 2, Multi-Center, Randomized, Double-Masked, Active Controlled Study of ADVM-022 (AAV.7m8-aflibercept) in Subjects With Diabetic Macular Edema [INFINITY]

Study Description

A Phase 2, Multi-Center, Randomized, Double-Masked\*, Active Controlled Study of ADVM-022 (AAV.7m8-aflibercept) in Subjects with Diabetic Macular Edema \[INFINITY\]

Study Details

Registry ID:

NCT04418427

Conditions:

Diabetic Macular Edema, Diabetic Retinopathy

Phase:

Phase 2

Target Enrollment:

36 participants

Start Date:

May 28, 2020

Age Range:

18–999 years

Healthy Volunteers:

No

Study Locations (15 sites)

• Adverum Clinical Site
  AreciboPuerto Rico, Puerto Rico
• Adverum Clinical Site
  AreciboPuerto Rico, Puerto Rico
• Adverum Clinical Site
  Deerfield Beach, FloridaUnited States, United States
• Adverum Clinical Site
  Philadelphia, PennsylvaniaUnited States, United States
• Adverum Clinical Site
  West Columbia, South CarolinaUnited States, United States
• Adverum Clinical Site
  Nashville, TennesseeUnited States, United States
• Adverum Clinical Site
  Houston, TexasUnited States, United States
• Adverum Clinical Site
  The Woodlands, TexasUnited States, United States
• Adverum Clinical Site
  Austin, TexasUnited States, United States
• Adverum Clinical Site
  Abilene, TexasUnited States, United States
• Adverum Clinical Site
  Golden, ColoradoUnited States, United States
• Adverum Clinical Site
  Phoenix, ArizonaUnited States, United States
• Adverum Clinical Site
  Beverly Hills, CaliforniaUnited States, United States
• Adverum Clinical Site
  Bakersfield, CaliforniaUnited States, United States
• Adverum Clinical Site
  Reno, NevadaUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →